A Phase Ib Trial of BYL719 (an alpha-Specific PI3K Inhibitor) in Combination With Endocrine Therapy in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

Trial Profile

A Phase Ib Trial of BYL719 (an alpha-Specific PI3K Inhibitor) in Combination With Endocrine Therapy in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Alpelisib (Primary) ; Letrozole
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 10 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Jun 2017 Biomarkers information updated
    • 06 May 2016 Planned number of patients changed from 30 to 47.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top